GlassScriptPhysician profile
Barnett R Kantz
NPI 1275509432
$10,336.07
in general payments reported to CMS, 2019-2025
44 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $1,089 · 2021: $1,562 · 2022: $1,459 · 2023: $1,871 · 2024: $1,675 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,535 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,534.54 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,296.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,264.11 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $1,023.61 | 2019-2025 | |
| Lilly USA, LLC | $879.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $876.23 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $702.86 | 2019-2025 | Jardiance, Spiriva Respimat, Glyxambi |
| Glaxosmithkline, LLC. | $598.32 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $357.22 | 2024-2025 | Auvelity, Symbravo |
| Exact Sciences Corporation | $324.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $318.92 | 2019-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $273.27 | 2023-2025 | Caplyta |
| Amarin Pharma, INC. | $259.46 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $224.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $178.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $172.92 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143.18 | 2020-2024 | Evenity, Prolia |
| Collegium Pharmaceutical, INC. | $116.73 | 2024-2025 | Belbuca, Xtampza |
| Teva Pharmaceuticals USA, INC. | $114.93 | 2019-2025 | Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $93.24 | 2021-2024 | |
| Dexcom, INC. | $91.82 | 2021-2023 | Dexcom G6 Transmitter |
| Impel Pharmaceuticals INC. | $88.37 | 2023 | Trudhesa |
| Allergan, INC. | $87.72 | 2020 | |
| Currax Pharmaceuticals LLC | $79.45 | 2023 | Nexletol, Contrave, Nexlizet |
| Alkermes, INC. | $70.76 | 2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $70.07 | 2022-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $57.24 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $56.20 | 2024-2025 | Zoryve |
| Corcept Therapeutics | $53.24 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $45.42 | 2025 | Rexulti |
| Ardelyx, INC. | $44.63 | 2024-2025 | Ibsrela |
| Zyla Life Sciences, INC. | $44.16 | 2020 | |
| Eisai INC. | $41.14 | 2020-2021 | |
| Abbott Laboratories | $39.30 | 2023 | Freestyle Libre 3 |
| Viatris Specialty LLC | $31.84 | 2025 | Yupelri |
| Cequr Corporation | $31.64 | 2024 | Cequr Simplicity |
| Horizon Therapeutics Plc | $29.60 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.24 | 2020 | |
| Shield Therapeutics INC | $26.85 | 2022-2023 | Accrufer |
| Fisher & Paykel Healthcare INC | $19.77 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.66 | 2023 | Unithroid |
| Phadia US INC. | $19.63 | 2023 | Immunocap |
| Arbor Pharmaceuticals, INC. | $14.50 | 2021 | |
| Antares Pharma, INC. | $14.18 | 2023 | Nocdurna, Tlando, Xyosted |
| Ibsa Pharma INC. | $11.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barnett Kantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.